Drugs / DFF332
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04895748 | Nov 2021 → Feb 2026 | clear cell renal carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFF332 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895748 ↗ |
| Action | Inhibit | “Hif2alpha inhibitor” NCT04895748 ↗ |
| Modality | Small molecule | “This was a first in human study of DFF332, a small molecule that targets a protein called HIF2α.” NCT04895748 ↗ |